# Biostar

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biostar

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.biostar-pharm.com
- Total disclosed funding: $150M
- Latest round: Series E (Nov 26, 2020)
- Investors on record: 17

## About

Established in 2002 and based in Beijing, China, Biostar operates as a biopharmaceutical company that mainly provides microbial small molecule antitumor innovative drugs. It has a research and development base in Beijing, a subsidiary and industrialization base in Chengdu, and a branch in Burlingame. The chairman, CSO, and CMO of the company, Li Tang graduated from the University of Wisconsin. In October 2024, Biostar raised USD 23 million in pre-IPO funding and listed on the Hong Kong Exchanges and Clearing Limited.

The company mainly provides antitumor innovative drugs. It uses three technology platforms to develop new drugs, which are combined biosynthesis technology platform, microbial fermentation production technology platform, and microbial drug preparation development platform. Products include injections, capsules, antibody-drug conjugates, etc. The product is suitable for advanced breast cancer, solid tumours, gliomas, breast cancer brain metastasis, and other tumour diseases.

The company generates revenue by providing antitumor innovative drugs such as injections, capsules, and antibody-drug conjugates.

The company will use IPO funding to fund clinical trials of core products, strengthen commercialization capabilities and establish a global marketing network, expand production capacity, and be used for working capital and general corporate purposes.

## Funding rounds

- Series E, Nov 26, 2020, $135M — CCB International Asset Management, Shanghai Jianyi Private Equity Fund Management, MPC, Yifeng Capital, Chengdu Venture Capital, Koffie Insurance, Inc.
- Series C, Apr 24, 2019 — Lapam Capital
- Series C, Jan 15, 2019 — Detong Capital, Neovision Capital, SDIC Venture Capital, Chengdu Venture Capital
- Series B, Aug 22, 2018 — Lapam Capital, Tibet Xinsheng Deyuan Venture Investment Management
- Series B, Aug 14, 2017, $15M — Betta Pharmaceuticals, Star Capital, Yanyuan Venture Capital
- Series A, Feb 18, 2016 — Fortune Capital, Biossom Investment Management, Xiamen Yingyan Technology
- Angel, Dec 23, 2013 — Lapam Capital

## Investors

- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Angel, Series B, Series C
- Fortune Capital — Series A
- Biossom Investment Management (https://capitalatlas.ai/funds/biossom-investment-management) — Series A
- Xiamen Yingyan Technology — Series A
- Betta Pharmaceuticals — Series B
- Star Capital — Series B
- Yanyuan Venture Capital — Series B
- Tibet Xinsheng Deyuan Venture Investment Management — Series B
- Detong Capital (https://capitalatlas.ai/funds/detong-capital) — Series C
- Neovision Capital (https://capitalatlas.ai/funds/neovision-capital) — Series C
- SDIC Venture Capital (https://capitalatlas.ai/funds/sdic-venture-capital) — Series C
- Chengdu Venture Capital (https://capitalatlas.ai/funds/chengdu-venture-capital) — Series C, Series E
- CCB International Asset Management (https://capitalatlas.ai/funds/ccb-international-asset-management) — Series E
- Shanghai Jianyi Private Equity Fund Management (https://capitalatlas.ai/funds/shanghai-jianyi-private-equity-fund-management) — Series E
- MPC — Series E
- Yifeng Capital — Series E
- Koffie Insurance, Inc. — Series E